Core Viewpoint - The announcement highlights a significant contract signed by the company's wholly-owned subsidiary, Ausino, which is expected to contribute positively to the company's revenue and market position in the pharmaceutical supply chain [1][2]. Group 1: Contract Details - The contract signed on May 22, 2023, involves a total amount of approximately $102 million (including tax), with an actual performance amount of about $20 million (approximately RMB 143.53 million) for the year 2025, representing 8.83% of the company's audited revenue for 2024 and 29.05% of customized products and services revenue [1]. - The actual performance amount for 2025 exceeds the procurement guidance of $12.15 million by 65.43%, showcasing the company's technical strength and market competitiveness [1]. Group 2: Financial Impact - The successful execution of this contract is expected to have a positive impact on the company's operating performance for 2025, enhancing its sustainability and brand influence while expanding its overseas market [2]. - In the first three quarters of 2025, the company achieved revenue of RMB 1.527 billion, a year-on-year increase of 21.95%, and a net profit attributable to the parent company of RMB 445 million, up 26.92% year-on-year [2]. Group 3: International Strategy - The company has positioned internationalization as a core strategy, leveraging its technological advantages and production capacity to accelerate global market penetration [2]. - The company has established a sales network covering Europe, Latin America, India, and Africa, with peptide raw materials exported to 22 countries, including the United States, Europe, and Canada [2]. - The excess performance of the significant contract further validates the company's capability in expanding its overseas business [2].